Literature DB >> 11353641

Antibacterial properties of gemifloxacin and trovafloxacin in urine ex vivo: phase I study.

G García-Calvo1, A Parra, L Aguilar, C Ponte, M J Giménez, A Carcas, M Kinzig-Schippers, F Soriano.   

Abstract

Urine bactericidal titers (UBTs) against Escherichia coli ATCC 25922 and Staphylococcus saprophyticus ATCC 1970 were determined after the administration of single oral doses of gemifloxacin at 320 mg and trovafloxacin at 200 mg to healthy volunteers. Gemifloxacin presented significantly lower experimental versus mathematically predicted UBTs over 72 h, due to the effect of urine on the susceptibility of the E. coli strain. Experimental UBTs were significantly higher for gemifloxacin than trovafloxacin against both strains over 72 h.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353641      PMCID: PMC90561          DOI: 10.1128/AAC.45.6.1876-1878.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Correlation of predicted serum bactericidal activities and values measured in volunteers.

Authors:  G Drusano; H Standiford; P Ryan; W McNamee; B Tatem; S Schimpff
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

2.  Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections.

Authors:  J Klastersky; D Daneau; G Swings; D Weerts
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

3.  Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.

Authors:  L Aguilar; I P Balcabao; P Salvá; M Martín; J Costa; J Prieto; R Dal-ré
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

4.  Antibacterial activity after a single-dose of norfloxacin, ofloxacin and pipemidic acid detected in urine of volunteers.

Authors:  M Cruciani; V Monzillo; A Navarra; C Tinelli; E Concia
Journal:  Drugs Exp Clin Res       Date:  1988
  4 in total
  1 in total

1.  Design and virtual screening of novel fluoroquinolone analogs as effective mutant DNA GyrA inhibitors against urinary tract infection-causing fluoroquinolone resistant Escherichia coli.

Authors:  Sakthivel Balasubramaniyan; Navabshan Irfan; Appavoo Umamaheswari; Ayarivan Puratchikody
Journal:  RSC Adv       Date:  2018-06-29       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.